Key result
A combined regimen of half-dose tPA and tirofiban given intravenously successfully achieved complete resolution of embolic thrombi in a patient with a mitral valve prosthesis.
Why the study?
Does a combined regimen of half-dose tPA and tirofiban improve angiographic resolution of coronary embolism in a patient with a mitral valve prosthesis?
Case Report (n=1)
Does a combined regimen of half-dose tPA and tirofiban improve angiographic resolution of coronary embolism in a patient with a mitral valve prosthesis?
A combined intravenous regimen of half-dose tPA and tirofiban successfully resolved a coronary embolism secondary to a prosthetic mitral valve without causing bleeding complications.
Answers are grounded in this paper and cite their sources.
May support combined half-dose tPA plus tirofiban for coronary embolism from mitral prosthesis; hypothesis-generating and requires confirmation.
Coronary embolism has been considered as a rare cause of coronary occlusion. Prosthetic heart valve is an infrequent cause of this condition. The exact incidence of coronary embolization in patients with prosthetic heart valves is not well known. Furthermore, the effective treatment and management of coronary emboli in this setting remains unknown. It is the purpose of this paper to report the successful management of a case of coronary embolism with half-dose tissue-type plasminogen activator (tPA) and tirofiban given intravenously in a patient with mitral valve prosthesis. CASE REPORT A 54-year-old man with mitral valve prosthesis and DDD pacemaker was admitted to our hospital on October 18, 2005 complaining of a sudden onset of severe chest pain that began four hours prior to admission. He had no history of coronary artery disease, diabetes mellitus, hypertension, or hypercholesterolemia. He had a history of hypertrophic obstructive cardiomyopathy and third degree mitral regurgitation for ten years. Four years prior to the admission, he underwent DDD pacemaker implantation because of symptoms related to hypertrophic cardiomyopathy. Since the pressure gradient between the left ventricle and aorta did not decrease, the patient underwent open heart operation for septal myectomy and mitral valve replacement (St. Jude, USA) in the same year. Coronary angiogram, previously performed as a part of the preoperative catheterization study, had been normal. He had been maintained on warfarin therapy, but reported having stopped his medication 3 weeks prior to the admission. Upon admission to the hospital, ECG showed left bundle branch block and sinus rhythm with 84/min. Physical examination revealed acutely ill, pale, diaphoretic man with a blood pressure of 140/90 mmHg. Examination of the heart revealed normal opening and closing clicks of the mitral prosthesis and a four heart sound; no murmurs were heard. The lungs were clear to auscultation. Initial troponin I, creatine kinase (CK) and creatine kinase-MB (CK-MB) levels were 8.565 ng/ml, 1337 IU/L and, 236 ng/ml respectively. International normalized ratio (INR) was 1.1. Clinical presentation and laboratory data indicated that acute myocardial infarction was suspected. Urgent coronary angiography was performed 6 hours after the onset of chest pain. Coronary angiography was normal except for thrombi in the proximal part of the left anterior descending coronary and ramus arteries (Fig. A). After initial attempt to retrieve of the emboli via angiojet thrombectomy system failed, a combined regimen of half-dose tPA (15 mg i.v. bolus plus 35 mg i.v. infusion for 1 hour) and tirofiban (30-minute loading infusion of 0.6 μg·kg−1·min−1 followed by a maintenance infusion of 0.15 μg·kg−1·min−1 with heparin) were given intravenously. In addition, the patient was treated with aspirin, beta-blocker, and nitroglycerine. On the third day of tirofiban infusion, coronary angiography revealed incomplete resolution of the emboli (Fig. B). After 108 hours, tirofiban was discontinued, but heparin was administered for a whole week. Coronary angiogram repeated on the seventh day showed complete resolution of the thrombi (Fig. C). No bleeding complications were observed during the hospitalization period. The patient was discharged on warfarin, aspirin, and beta-blocker therapy.Fig. A:: Embolic thrombi in the proximal part of the left anterior descending and ramus arteries; B: incomplete resolution of the thrombi in the third day of tirofiban infusion; C: complete resolution of the thrombi.DISCUSSION Coronary embolism was first described by Virchow in 1856.1 Since then it has been reported clinically and from postmortem studies, and in 1958 Wengere and Bauer, reviewing the literature, found about 60 well documented cases and several necropsy studies.1 The most common cause of coronary embolism was bacterial endocarditis, and others included rheumatic heart disease, dilated cardiomyopathy, left atrial myxoma, arrhythmias and myocardial infarction.2 Since the advent of prosthetic valvular surgery, another source for coronary emboli has been introduced, that is, fragments of the prosthetic material or more commonly thrombus formed at the surface of the prosthesis. In 1964, Bjork and Malers3 reported the first case of coronary embolism arising from a mitral prosthesis. The consequences of coronary embolism depend on two major factors: the size of the embolus and the size of the lumen of the artery in which it becomes impacted.4 The smaller the embolus, the greater is the chance that it will travel distally to a small coronary arterial segment and the less is the likelihood of myocardial infarction or fatal arrhythmia.4 Currently, there is no clear guideline for the effective treatment and management of coronary emboli. Kamishirado et al5 reported a case of coronary artery embolism that were not recannulized with 960 000 IU of urokinase. In another case, coronary embolization secondary to aortic valve endocarditis was treated with standard doses of streptokinase and aspirin.6 The patient survived but sustained a large myocardial infarction and a major gastrointestinal bleeding. Glycoprotein IIb/IIIa antagonists have been evaluated in many clinical trials. The findings in these trials show that patients undergoing percutaneous transluminal coronary angioplasty (PTCA) benefit from these agents. It has been common experience of cardiologists that thrombi seen during coronary intervention procedures are reduced or eliminated by this agent, so that it was felt to be logical to employ it in this setting. Prolonged infusion with urokinase has been found to be useful in eliminating thrombus from saphenous vein grafts.7 Recently, it has been shown that combined regimen of intracoronary urokinase and intravenous abciximab is found to be successful in achieving complete resolution of the emboli in a patient with mitral and aortic valve replacement.8 We also found that the use of combined regimen of half-dose tPA and tirofiban given intravenously was effective for the complete resolution of embolic thrombi secondary to mitral valve prosthesis. It is not certain that the combined use of these drugs was preferable to using either one alone, and the combination may have increased the potential risk of bleeding complications. However, the ominous appearance of the larger embolus prompted this aggressive anti-thrombotic approach. In summary, coronary embolism secondary to prosthetic valve is an uncommon etiology of myocardial infarction. A combined regimen of half-dose tPA and tirofiban given intravenously may be an effective treatment of this condition. The outcome looks gratifying. Nevertheless, it is uncertain as to the relative importance of the antiplatelet and the thrombolytic agent in clearing the emboli.
No takes yet. Share an insight, caveat, or question.
Atmaca et al. (2007) conducted a case report in Coronary embolism (n=1). Half-dose tissue-type plasminogen activator (tPA) and tirofiban was evaluated on Resolution of embolic thrombi. A combined regimen of half-dose tPA and tirofiban given intravenously successfully achieved complete resolution of embolic thrombi in a patient with a mitral valve prosthesis.
Synapse has enriched 10 related papers. Consider them for comparative context: